Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells

Downregulation of MHC class I (MHCI) molecules on tumor cells is recognized as a resistance mechanism of cancer immunotherapy. Given that MHCI molecules are potent regulators of immune responses, we postulated that the expression of MHCI by tumor cells influences systemic immune responses. According...

Full description

Bibliographic Details
Main Authors: Juan Gao, Andreas Lundqvist, Xu Jing, Yihai Cao, Le Tong, Shi Yong Neo, Dongmei Tong, Ziqing Chen, Mireia Cruz De Los Santos, Nutsa Burduli, Sabrina De Souza Ferreira, Arnika Kathleen Wagner, Evren Alici, Charlotte Rolny
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/10/e005308.full

Internet

https://jitc.bmj.com/content/10/10/e005308.full

Similar Items